NCT02346201 / ADMET 2

Study ID(s) and Acronym(s)
NCT02346201 / ADMET 2 / ADMET2
Current Status of Trial
Completed
Study Aim
Treatment Dementia
Study Design
RCT
Blinding
Double-blind
Intervention type
Pharmacological
Intervention
Methylphenidate // Placebo
Dosage and Duration
20 mg/day methylphenidate on symptoms of apathy over 6 months in patients with mild to moderate Alzheimer's disease (AD)
Absolute Number of Participants
200
Health Status/Diagnosis
Alzheimer Disease (AD)
Country or Countries of Recruitment
United States
Primary outcomes
Neuropsychiatric Inventory (NPI) // Clinical Global Impression of Change (CGIC)